Darifenacin [Enablex, Emselex], a muscarinic M3-selective receptor antagonist, improves symptoms in patients with overactive bladder, according to studies presented at the 99th Annual Meeting of the American Urological Association (AUA) [San Francisco, US; May 2004]. A pooled analysis of data from three phase III studies involving a total of > 1000 patients showed that once-daily treatment with darifenacin 7.5mg or 15mg produced significant reductions in incontinence episodes, micturition frequency and urinary urgency. Another study presented at the meeting showed that the incidence of nocturia, a core symptom of overactive bladder, was significantly reduced in darifenacin, compared with placebo, recipients.